Evaluating evidence from a decision analysis

Journal of the American Board of Family Practice

Volumn 12, Issue 5, 1999, Pages 395-402

  Ramsey, Scott D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; DECISION SUPPORT SYSTEM; DECISION TREE; EVIDENCE BASED MEDICINE; HUMAN; LYME DISEASE; MALE;

ADULT; DECISION SUPPORT TECHNIQUES; DECISION TREES; EVIDENCE-BASED MEDICINE; HUMANS; LYME DISEASE; MALE;

EID: 0033194097     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: 10.3122/jabfm.12.5.395     Document Type: Article

References (27)

1. Nichol G, Dennis DT, Steere AC, et al. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1998;128:37-48.
2. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994.
3. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. New York, Edinburgh: Churchill Livingstone, 1997.
4. Dowie J. Evidence based medicine: needs to be within framework of decision making based on decision analysis. BMJ 1996;313:170-1.
5. Kassirer JP, Moskowitz AJ, Lau J, Pauker SG. Decision analysis: a progress report. Ann Intern Med 1987;106:275-91.
6. Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group. JAMA 1995;273:1610-3.
7. Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1995;273:1292-5.
8. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders, 1980.
9. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-26.
10. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996;124:400-6.
11. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617-24.
12. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
13. Hailey D, Sampietro-Colom L, Marshall D, Rico R, Granados A, Asua J. The effectiveness of bone density measurement and associated treatments for prevention of fractures. An international collaborative review. Int J Technol Assess Health Care 1998;14:237-54.
14. Tosteson AN, Rosenthal DI, Melton LJ 3rd, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594-603.
15. Eddy DM. Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 1990;263:3077, 3081, 3084.
16. Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol 1996;91:1773-7.
17. Briggs AH, Sculpher MJ, Logan RP, Aldous J, Ramsay ME, Baron JH. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 1996;312:1321-5.
18. O'Brien B. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Med Care 1996;34(12 Suppl):DS99-DS108.
19. Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994;120:667-76.
20. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev 1992;14:154-76.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
22. Gold MR, Siegel JE, Russell LB, Weinstein MC editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
23. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 1997;278:1745-8.
24. Naimark DM, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 1994;9:702-7.
25. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy for various coronary heart disease risk factor modifications. Circulation 1991;83:1194-201.
26. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-603.
27. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.